UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. (Exact name of registrant as specified in its charter) Delaware 46-5211056 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (Address of principal executive offices) (Zip Code) (210) 698-5334 OR ...

Financial Performance - Total product revenue for the year ended December 31, 2024, was $35.6 million, an increase of $4.5 million, or 15%, compared to $31.1 million in 2023[252]. - Gross profit for the year ended December 31, 2024, was approximately $25.1 million, an increase of $3.2 million, or 14%, compared to $22.0 million in 2023[256]. - Loss from operations improved by 47% to approximately $16.8 million for the year ended December 31, 2024, down from $31.9 million in 2023, due to revenue growth and a 22% reduction in total operating expenses[260]. - The company experienced a loss on foreign currency transactions of approximately $4.2 million for the year ended December 31, 2024, compared to a gain of approximately $1.9 million in 2023[262]. - The company recorded approximately $3.76 million in stock-based compensation expense for the year ended December 31, 2024, including 1,214,400 performance awards granted[280]. Expenses Management - Research and development expenses decreased by approximately $8.7 million, or 56%, to $6.9 million for the year ended December 31, 2024, primarily due to the completion of the STAR-T clinical trial[257]. - Selling, general and administrative expenses decreased by approximately $3.3 million, or 9%, to $35.0 million for the year ended December 31, 2024, mainly due to reductions in salaries and professional expenses[259]. - The company continues to manage resources proactively, focusing on regulatory submissions and maintaining tight control over expenditures[268]. - The company has adjusted its accounting policy for grants, retroactively reclassifying grant income as a reduction of research and development expenses[279]. Financing Activities - The company secured a $20 million credit facility in June 2024, with an initial tranche of $15 million available at closing[266]. - The company raised a total of $7.3 million through the Rights Offering and Series A Right Warrants, increasing unrestricted cash to $15.6 million as of December 31, 2024, compared to $3.3 million previously reported[270]. - The Rights Offering closed on January 10, 2025, raising gross proceeds of $6.25 million from the sale of 6.25 million Units, each comprising one share of common stock and two Right Warrants[271]. - Approximately 1.4 million Series A Right Warrants were exercised at an exercise price of $1.13 per warrant, generating an additional $1.6 million in gross proceeds[271]. - The Avenue Capital Group has committed to loan the company up to $20 million, with $15 million available in the first tranche and a second tranche of up to $5 million contingent on FDA approval[273]. - The proceeds from the Avenue Capital Commitment will be used to pay off existing debt and for working capital, with interest rates set at a minimum of 5% above the Prime Rate or 13.5%[275]. - The company is actively pursuing various financing sources, including equity and debt financing, to meet its increasing capital needs[272]. Regulatory and Operational Updates - The company submitted a De Novo medical device application for DrugSorb-ATR to the FDA on September 27, 2024, which was accepted for substantive review in October 2024[250]. - The company expects to receive regulatory approval for DrugSorb-ATR in the U.S. and Canada in 2025, which is critical for future capital requirements[272]. - As of December 31, 2024, the company had current assets of approximately $21.6 million and current liabilities of approximately $9.9 million[264]. - The company operates leased facilities in Princeton, New Jersey, and Berlin, Germany, with a monthly base rent of approximately $121,000 as of December 31, 2024[283].

EX-99.1 2 ped_ex991.htm PRESS RELEASE EXHIBIT 99.1 PEDEVCO Announces 2024 Financial Results HOUSTON, TX / ACCESSWIRE / March 31, 2025 / PEDEVCO Corp. (NYSE American: PED) ("PEDEVCO" or the "Company"), an energy company engaged in the acquisition and development of strategic, high growth energy projects in the U.S., today announced its financial results for the year ended December 31, 2024. Key Highlights Include: J. Douglas Schick, President and Chief Executive Officer of the Company, stated, "We are please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-41778 LQR House Inc. (Exact name of registrant as specified in its charter) Nevada 86-1604197 (State or other jurisdicti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 333-249833 Crown Electrokinetics Corp. (Exact name of registrant as specified in its charter) | Delaware | 47-5423944 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ____________ Commission file number: 001-35922 PEDEVCO Corp. (Exact Name of Registrant as Specified in Its Charter) Texas 22-3755993 (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ (Address of principal executive offices) (Zip Code) (206) 455-9504 (Regist ...

FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO _______ Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading symbol(s) | Name of each exchange on which registered | | --- | --- ...

Financial Performance - The Company incurred a net loss of approximately $5.6 million in 2024, with an accumulated deficit of approximately $277 million as of December 31, 2024[146]. - The Company's quarterly and annual operating and financial results are likely to fluctuate significantly due to various external factors[147]. - The Company expects its cash and cash equivalents of $17.2 million as of December 31, 2024, to fund operations for at least the next twelve months[148]. - The company reported goodwill of $8.4 million as of December 31, 2024, which is subject to impairment assessments that could adversely affect future earnings[172]. - Approximately 14% of the Company's revenue for the fiscal year ended 2024 was derived from customers outside of the U.S., primarily in Europe[182]. - The company sold 1,057,814 shares of its common stock at a weighted average price of $2.18 per share, resulting in cash proceeds of $2.0 million for the year ended December 31, 2023[243]. Revenue and Market Risks - The Company has paused U.S. sales of its ProFound AI® Risk product pending FDA regulatory clearance, which may impact future revenue[152]. - The markets for the Company's products may not develop as expected, leading to barriers in achieving broad market acceptance[156]. - The Company relies on a limited number of customers for a significant portion of its total revenue, making it vulnerable to the loss of key clients[146]. - The company's revenue from OEM partners accounted for 26% of total revenue in 2024, with GE Healthcare contributing 17%[170]. - The market for full field digital mammography systems and related products is crucial for the company's future growth, but may not develop as anticipated due to economic conditions and reimbursement issues[169]. - The healthcare industry consolidation could reduce the Company's potential customer base and demand for its systems, impacting revenue generation[188]. Operational and Compliance Risks - The Company faces legal, business, and operational risks associated with the use of AI and machine learning technologies in its offerings[146]. - The Company may be exposed to significant product liability claims, which could harm its reputation and financial condition[160]. - The Company must comply with Nasdaq's continued listing requirements, including maintaining a minimum closing bid price of $1.00 per share[196]. - The healthcare industry is subject to extensive regulation, and non-compliance could result in significant costs, including fines and exclusion from government healthcare programs[205]. - The Company’s CAD systems are classified as medical devices and are subject to extensive FDA regulation, which includes manufacturing operations and product labeling[214]. - Regulatory changes or challenges could adversely affect the Company’s ability to commercialize existing and future products, impacting revenue generation[212]. - The Company may face substantial costs related to compliance with evolving privacy and data protection laws, including HIPAA[226]. - The Company’s operations are subject to audits and investigations from government agencies, which could disrupt business and lead to significant defense costs[209]. - The Company may incur substantial expenses if claims arise regarding the wrongful use or disclosure of confidential information by its employees[187]. - Compliance with healthcare fraud and abuse laws could restrict the Company’s sales and marketing practices, leading to potential legal and financial repercussions[211]. Strategic and Developmental Challenges - The Company is transitioning to a software as a service (SaaS) model, which may impact revenue recognition and cash flow[141]. - The Company is transitioning to a subscription licensing model, which may lead to unpredictable revenue due to limited operating history with this model[171]. - The Company is developing a new product in collaboration with Solis to detect BAC using mammography, but regulatory approval and market acceptance are uncertain[164]. - The Company’s ability to adapt to evolving technologies is critical, as failure to do so may render its products obsolete and negatively impact business[176]. - Clinical trials are expensive and lengthy, with uncertain outcomes that could delay regulatory approvals and revenue generation[189]. - Strategic transactions, such as acquisitions or joint ventures, could disrupt operations and may not yield the anticipated benefits[220]. Financial and Market Conditions - The Company may need to seek additional capital sooner than planned to fund product development and commercialization[149]. - The Company may experience fluctuations in its effective tax rate due to various factors, including changes in geographic earnings mix and tax law changes[173]. - The Company is exposed to competitive pressures from larger firms with greater resources, which could adversely affect its market position[178]. - Changes in credit ratings could lead to increased borrowing costs and limit financing options, potentially affecting the Company's operational flexibility[253]. - Unfavorable global economic conditions, including geopolitical events and inflationary pressures, could weaken demand for the Company's products and impact capital raising efforts[254]. - The Trump administration's proposed tariffs on imports from various countries could significantly affect the U.S. healthcare industry, with potential downstream impacts on the Company[255]. Cybersecurity and Data Protection - The Company faces risks related to cybersecurity incidents that could compromise customer data and result in significant liabilities[247]. - The Company may face significant capital expenditures to protect against security breaches and hackers due to vulnerabilities in its infrastructure and systems[180]. - The European Union's General Data Protection Regulation (GDPR) imposes penalties of up to 4% of worldwide revenue for non-compliance[234]. - The EU AI Act, published in 2024, may impose fines of up to 7% of worldwide annual turnover for breaches related to AI regulations[232]. - The Company is subject to complex regulations regarding AI and machine learning, which may require operational changes and increase costs[232]. Management and Governance - The Company underwent management changes, including the Chief Executive Officer and Chief Financial Officer, during the year ended December 31, 2023[192]. - The Company is classified as a "smaller reporting company," which may make its stock less attractive to investors due to reduced disclosure requirements[244]. - Future issuances of common stock may cause significant dilution of existing shareholders' equity interests[242]. - The Company has the ability to issue up to 1,000,000 shares of preferred stock, which could affect existing stockholders' rights[237]. - The Company's stock price has experienced volatility, which may impair its ability to finance strategic transactions[240]. - The Company is required to assess the effectiveness of its internal controls over financial reporting as per Section 404 of the Sarbanes-Oxley Act, dedicating significant resources for compliance for the year ended December 31, 2024[252].

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ OR ☐ SHELL COMPANY REPORT PURSUANT TO S ...